Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Renal cell carcinoma (RCC) is a common lethal urological cancer,the distant metastasis of which is the leading cause of death.Although targeted agents have remarkably improved the overall prognosis of RCC patients,nearly all the patients eventually acquire therapeutic resistance.With the advent of immune checkpoint inhibitors,immunotherapy based on tumor microenvironment (TME) has shown a broad scope in clinical application.The deepening understanding of TME leads to the changes of therapeutic strategies for advanced RCC,and the combination of targeted therapy and immunotherapy is exhibiting a promising prospect.Herein,we reviewed the TME characteristics,candidate predictive biomarkers,and possible targets for future development of drugs against RCC.

Citation

Song-Chen Han, Hua-Qi Yin, Tao Xu. Immunotherapy Based on Tumor Microenvironment in Renal Cell Carcinoma]. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae. 2022 Apr;44(2):305-312

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 35538767

View Full Text